Plant Name: Plantago depressa
Taxonomic Information:
Plant ID: NPO8918
Plant Latin Name: Plantago depressa
Taxonomy Genus: Plantago
Taxonomy Family: Plantaginaceae
Plant External Links:
NCBI TaxonomyDB:
411227
Plant-of-the-World-Online:
685094-1
Used in Medicines:
Country/Region:
China; IndiaTraditional Medicine System:
Indian Folk; TCMMedicinal Functions:
Laxative
Geographical Distribution:
India; China; Russia; South Africa
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HRH3; HRH4; HRH1; | |
| ACHE; | |
| CDC25B; | |
| BLM; HSD17B1; GFER; ALOX15; | |
| CSNK2A1; | |
| NR1H4; | |
| ESR2; | |
| NFKB1; | |
| LMNA; FABP4; THPO; | |
| L3MBTL1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Small molecule receptor (family A GPCR) | HRH3 | Histamine H3 receptor | Q9Y5N1 | CHEMBL264 |
| Small molecule receptor (family A GPCR) | HRH4 | Histamine H4 receptor | Q9H3N8 | CHEMBL3759 |
| Small molecule receptor (family A GPCR) | HRH1 | Histamine H1 receptor | P35367 | CHEMBL231 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.905E-11 | 8.292E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.395E-09 | 1.013E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.966E-08 | 7.512E-05 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0004969; histamine receptor activity | 2.559E-08 | 7.960E-05 | HRH1, HRH3, HRH4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.531E-07 | 2.564E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.842E-07 | 3.868E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.683E-06 | 1.551E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 1.781E-06 | 1.551E-03 | ACHE, ALOX15, CSNK2A1, CYP19A1, CYP1A1, CYP3A4, HSD17B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.238E-06 | 1.805E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 2.520E-06 | 1.855E-03 | CYP3A4, ESR2, HSD17B1, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 3.278E-06 | 2.302E-03 | CYP19A1, CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.712E-06 | 2.493E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 7.420E-06 | 3.798E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 7.420E-06 | 3.798E-03 | CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.236E-05 | 5.382E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.852E-05 | 7.688E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.852E-05 | 7.688E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 2.591E-05 | 9.958E-03 | CYP1A2, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 2.685E-08 | 2.443E-06 | AR, GSK3B, CDK6, FLT3, MMP2, PRKCA, PPARG, PTGS2, HIF1A, TP53, NFKB1, PPARD |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 7.017E-09 | 1.277E-06 | FABP2, FABP3, FABP4, FABP5, PPARG, PPARA, PPARD |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 7.866E-08 | 3.579E-06 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 7.169E-08 | 3.579E-06 | PLA2G1B, CYP1A2, ALOX15, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 7.774E-07 | 2.358E-05 | GSK3B, CDK6, CSNK2A1, RAB9A, TP53, NFKB1, TLR2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.203E-06 | 3.128E-05 | HSD17B1, CYP1A1, CYP1B1, PTGS2, CYP19A1 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.657E-06 | 3.769E-05 | ABCC1, CDK6, PIM1, CYP1B1, PRKCA, PTGS2, TP53, NFKB1, CDC25B |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 6.339E-07 | 2.307E-05 | CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP2C19, PTGS2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 3.548E-06 | 7.175E-05 | PLA2G1B, ALOX15, CYP2C19, PTGS2, PTGS1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 3.963E-06 | 7.213E-05 | MAOA, ALOX15, PRKCA, CYP2C19, PTGS2, PTGS1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 4.717E-05 | 7.153E-04 | PLA2G1B, MAOA, ALOX15, PTGS2, CYP2C19, CYP3A4, CYP19A1, PTGS1, PKM, AKR1B10, HSD17B1, CYP1A2, ALDH1A1, CYP1A1, XDH |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.505E-05 | 2.490E-04 | MAOA, CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 6.198E-05 | 8.057E-04 | FLT3, PIM1, NFKB1, PPARD |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.142E-04 | 1.155E-03 | MMP2, PRKCA, TP53, HIF1A, ESR1, TLR2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 5.779E-05 | 8.057E-04 | FABP4, PTGS2, TSHR, PTGS1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 8.151E-05 | 9.889E-04 | GSK3B, PRKCA, TP53, ESR1, HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.205E-04 | 1.155E-03 | POLB, CDK6, PKM, SYK, TP53, NFKB1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.038E-04 | 1.155E-03 | CYP1A2, ALDH1A1, CYP1A1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.169E-04 | 1.155E-03 | PKM, FLT3, TP53, HIF1A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 2.894E-04 | 1.951E-03 | GSK3B, CDK6, SYK, PRKCA, TP53, NFKB1, TLR2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 2.215E-04 | 1.551E-03 | CDK6, PRKCA, TP53, NFKB1, TLR2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04310 | Wnt signaling pathway | 1.947E-04 | 1.417E-03 | GSK3B, CSNK2A1, PRKCA, TP53, PPARD |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.547E-04 | 1.224E-03 | GSK3B, ESR1, NFKB1, ESR2 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.311E-04 | 1.193E-03 | MAOA, CYP1A2, CYP3A4, CYP2C19 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 1.465E-04 | 1.212E-03 | NR1H4, CYP3A4, CFTR, ABCG2 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.632E-04 | 1.238E-03 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 3.499E-04 | 2.196E-03 | GSK3B, AR, TP53, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 5.657E-04 | 3.321E-03 | MMP2, PIM1, PRKCA, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 3.069E-04 | 1.995E-03 | CDK6, PTGS2, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 6.049E-04 | 3.336E-03 | GABRR2, HRH1, HRH3, HRH2, HRH4, TSHR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 9.735E-04 | 5.062E-03 | GSK3B, SYK, CSNK2A1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 4.138E-04 | 2.510E-03 | SYK, CSNK2A1, PTGS2, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 7.536E-04 | 4.034E-03 | PTPN1, GSK3B, PPARA, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 1.079E-03 | 5.453E-03 | ABCC1, PRKCA, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 1.577E-03 | 7.360E-03 | GSK3B, PPARA, TP53, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04110 | Cell cycle | 1.218E-03 | 5.834E-03 | GSK3B, CDK6, TP53, CDC25B |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.872E-03 | 8.519E-03 | CDK6, PRKCA, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 1.217E-03 | 5.834E-03 | CDK6, PRKCA, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.956E-03 | 8.684E-03 | CDK6, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09131 Membrane transport | hsa02010 | ABC transporters | 6.006E-04 | 3.336E-03 | ABCC1, CFTR, ABCG2 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 1.377E-04 | 1.194E-03 | CYP1A2, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; HRH1; HRH3; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; HRH1; HRH3; |
| NA: NA | Perennial and seasonal allergic rhinitis | NA | HRH1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | HRH1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | HRH4; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; HRH1; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | HRH1; |
| NA: NA | Allergic disorders | NA | HRH1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; HRH3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Allergic skin disorders | L00-L99 | HRH1; |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | HRH1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | HRH1; |
| G00-G99: Diseases of the nervous system G00-G99 | Narcolepsy | G47.4 | HRH3; |
| NA: NA | Vasomotor rhinitis | NA | HRH1; |
| NA: NA | Respiratory allergies | NA | HRH1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | HRH3; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HRH3; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | HRH1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HRH1; HRH3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obese insulin-resistant disorders | E11 | HRH3; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; NFKB1; ACHE; HRH1; CDC25B; |
| H00-H59: Diseases of the eye and adnexa | Ocular allergy | H00-H59 | HRH1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | HRH3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | HRH1; |
| NA: NA | Common cold | NA | HRH1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | HRH1; HRH4; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HRH1; HRH3; |
| NA: NA | Morning sickness | NA | HRH1; |
| J00-J99: Diseases of the respiratory system | Seasonal and perennial allergic rhinitis and vasomotor rhinitis | J30 | HRH1; |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | HRH1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | HRH4; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | HRH1; HRH3; HRH4; |
| C00-D49: Neoplasms | Allergic conjunctivitis | C91.0, H10, H10.45, T78.4 | HRH1; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HRH3; |
| H60-H95: Diseases of the ear and mastoid process | Vertigo meniere's disease | H81, H81.0, R42 | HRH1; |
| NA: NA | Vertigo's disease | NA | HRH1; |
| NA: NA | Vomiting | NA | HRH1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Excessive daytime sleepiness | F51.1, G47.1 | HRH3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | HRH3; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Urticaria | NA | HRH1; |
| J00-J99: Diseases of the respiratory system | Hay fever | J30 | HRH1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HRH3; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | HRH3; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | HRH1; |
| NA: NA | Coughs | NA | HRH1; |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HRH1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Dry cough | R05 | HRH1; |
| NA: NA | Meniere's disease | NA | HRH1; |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | HRH1; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HRH3; |
| NA: NA | Hypersensitivity reactions | NA | HRH1; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | HRH3; |
| NA: NA | Itching | NA | HRH1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
